Stephen Horrigan

Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31

Stephen Horrigan, Zarema Arbieva, Hong Yan Xie et al. · Blood · 2000 · 110 citations

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

Warren Fiskus, S. Sharma, Saikat Saha et al. · Leukemia · 2014 · 95 citations · Full text

Hematological Malignancy, Oncology, Histone Deacetylase Inhibitor +9

The Smad5 Gene Is Involved in the Intracellular Signaling Pathways That Mediate the Inhibitory Effects of Transforming Growth Factor-β on Human Hematopoiesis

E Bruno, Stephen Horrigan, David Van Den Berg et al. · Blood · 1998 · 83 citations · Full text

A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31

Zhenbo Hu, Ignatius Gomes, Stephen Horrigan et al. · Oncogene · 2001 · 79 citations

Hematological Malignancy, Chromatin, Genetics +9

Characterization of an associated microfibril protein through recombinant DNA techniques.

Stephen Horrigan, Celeste B. Rich, Barbara W. Streeten et al. · Journal of Biological Chemistry · 1992 · 75 citations · Full text

Molecular Biology, Biofabrication, Molecular Genetics +24